Genetic modification immunotherapy for blood cancer is a technique that involves genetic modification of immune system T cells.It allows T cells to recognize weakly expressed antigens in the blood or other organs of the body, such as tumor cells.This form of immunotherapy can be divided into two types: one in which the patient receives genetically modified immune cells from a donor, and the other in which the patient's own immune cells are removed, genetically modified and then given back to the patient.CAR T cell therapy involves genetically altering immune system T cells to produce a protein called CAR or chimeric antigen receptor protein, which helps T cells attach to specific proteins on the surface of tumor cells, making it easier for them to recognize cancer cells.
This report contains market size and forecasts of Gene Modifying Immunotherapy for Blood Cancer in Global, including the following market information:
Global Gene Modifying Immunotherapy for Blood Cancer Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Gene Modifying Immunotherapy for Blood Cancer market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
CAR T-cell Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Gene Modifying Immunotherapy for Blood Cancer include Novartis, Kite Pharma, Juno Therapeutics, Cellectis, Ziopharm Oncology, Celyad, Bluebird Bio, Bellicum Pharmaceuticals and Mustang Bio. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Gene Modifying Immunotherapy for Blood Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Gene Modifying Immunotherapy for Blood Cancer Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Gene Modifying Immunotherapy for Blood Cancer Market Segment Percentages, by Type, 2021 (%)
CAR T-cell Therapy
TCR T-cell Therapy
Global Gene Modifying Immunotherapy for Blood Cancer Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Gene Modifying Immunotherapy for Blood Cancer Market Segment Percentages, by Application, 2021 (%)
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
B Cell Lymphoma
Multiple Myeloma
Other
Global Gene Modifying Immunotherapy for Blood Cancer Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Gene Modifying Immunotherapy for Blood Cancer Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Gene Modifying Immunotherapy for Blood Cancer revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Gene Modifying Immunotherapy for Blood Cancer revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Kite Pharma
Juno Therapeutics
Cellectis
Ziopharm Oncology
Celyad
Bluebird Bio
Bellicum Pharmaceuticals
Mustang Bio